Rk. Puri et al., A CHIMERIC PROTEIN COMPRISED OF IL-4 AND PSEUDOMONAS EXOTOXIN IS CYTOTOXIC FOR ACTIVATED HUMAN-LYMPHOCYTES, The Journal of immunology, 152(7), 1994, pp. 3693-3700
IL4-Pseudomonas exotoxin (IL4-PE4E) is a chimeric molecule in which hu
man IL-4 is genetically fused to the mutated binding domain of Pseudom
onas exotoxin. This molecule binds specifically to human IL-4 receptor
-bearing cells. IL4-PE4E was extremely cytotoxic to highly purified an
ti-CD3-activated CD8(+) T lymphocytes. The cytotoxic activity of this
molecule was dependent on the activation state of CD8(+) T cells: 3- a
nd 4-day activated T cells were very susceptible to the cytotoxic acti
vity of IL4-PE4E compared with 0- to 2-day activated cells. PHA-activa
ted lymphocytes and PBL activated in mixed lymphocyte reaction were al
so highly sensitive to IL4-PE4E. CD16(+) and/or CD56(+) highly purifie
d NK cells or highly purified, Ii-a-activated NK cells were also very
sensitive to the cytotoxic effect of IL4-PE4E. IL-2-activated LAK cell
s had little susceptibility after 1 day but were very sensitive to IL4
-PE4E after 3 days. The cytotoxic effects of IL4-PE4E were mediated th
rough a ligand receptor interaction because excess rIL-4 abrogated the
se effects as did a neutralizing Ab to human IL-4. A chimeric mutant p
rotein that can bind to IL-4 receptors but lacks the ability to inhibi
t protein synthesis was not cytotoxic to activated lymphocytes. The IL
4-PE4E-mediated cytotoxicity of activated T cells correlated with the
level of expression of IL-4 receptors on these cells. CD8+ T cells act
ivated for 3 days expressed the highest density of IL-4 receptors comp
ared with 1- or 2-day activated cells. Among two chimeric toxins teste
d only IL4-PE4E was cytotoxic to 2-day anti-CD3-activated CD8+ T lymph
ocytes, whereas IL6-PE4E was not active at all. These studies suggest
that human IL4 toxin could be a potent agent for the elimination of ac
tivated lymphocytes in allograft rejection, some autoimmune diseases,
or treatment of lymphomas and leukemias.